P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL
M. Amatangelo,
Y. Cheng,
W. Pierceall,
N. W. van de Donk,
S. Lonial,
M. Wang,
J. Emerson,
K. Hong,
P. Maciag,
T. Peluso,
A. Gandhi,
A. Thakurta
Affiliations
M. Amatangelo
1 Bristol Myers Squibb, Princeton, NJ, United States of America
Y. Cheng
1 Bristol Myers Squibb, Princeton, NJ, United States of America
W. Pierceall
1 Bristol Myers Squibb, Princeton, NJ, United States of America
N. W. van de Donk
2 Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, Netherlands
S. Lonial
3 Winship Cancer Institute, Emory University, Atlanta, GA, United States of America
M. Wang
1 Bristol Myers Squibb, Princeton, NJ, United States of America
J. Emerson
1 Bristol Myers Squibb, Princeton, NJ, United States of America
K. Hong
1 Bristol Myers Squibb, Princeton, NJ, United States of America
P. Maciag
1 Bristol Myers Squibb, Princeton, NJ, United States of America
T. Peluso
4 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
A. Gandhi
1 Bristol Myers Squibb, Princeton, NJ, United States of America
A. Thakurta
1 Bristol Myers Squibb, Princeton, NJ, United States of America
